Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
10601
PUT
BRC Inc
BRCC
$135M
| $138K | ﹤0.01% |
4,040
+1,730
| +75% | +$79.3K |
2022 Q1
10 quarters
|
|
|
PSTX
10602
CALL
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $138K | ﹤0.01% |
48,300
-86,400
| -64% | -$267K |
2024 Q1
2 quarters
|
|
|
BCYC
10603
PUT
Bicycle Therapeutics
BCYC
$265M
| $138K | ﹤0.01% |
6,100
+3,600
| +144% | +$83K |
2022 Q4
7 quarters
|
|
|
FNA
10604
CALL
DELISTED
Paragon 28, Inc.
FNA
| $138K | ﹤0.01% |
20,600
+19,600
| +1,960% | +$148K |
2022 Q4
7 quarters
|
|
|
BLUE
10605
PUT
DELISTED
bluebird bio
BLUE
| $138K | ﹤0.01% |
13,240
+1,740
| +15% | +$28.9K |
2014 Q2
41 quarters
|
|
10606
PUT
Arbutus Biopharma
ABUS
$826M
| $137K | ﹤0.01% |
35,700
+5,800
| +19% | +$22.2K |
2020 Q3
16 quarters
|
|
10607
CALL
Townsquare Media
TSQ
$80.8M
| $137K | ﹤0.01% |
13,500
-19,000
| -58% | -$204K |
2024 Q1
2 quarters
|
|
10608
PUT
VanEck Video Gaming and eSports ETF
ESPO
$248M
| $137K | ﹤0.01% |
+1,800
| New | +$125K |
2024 Q3
0 quarters
|
|
10609
CALL
Planet Labs
PL
$6.21B
| $137K | ﹤0.01% |
61,400
+56,300
| +1,104% | +$125K |
2021 Q4
11 quarters
|
|
10610
PUT
Denali Therapeutics
DNLI
$2.99B
| $137K | ﹤0.01% |
4,700
-3,600
| -43% | -$89.2K |
2022 Q2
9 quarters
|
|
10611
PUT
US Gold Corp
USAU
$230M
| $137K | ﹤0.01% |
23,500
+5,700
| +32% | +$31.9K |
2023 Q4
3 quarters
|
|
10612
CALL
BrightSpring Health Services
BTSG
$12.6B
| $137K | ﹤0.01% |
9,300
+7,400
| +389% | +$92.7K |
2024 Q1
2 quarters
|
|
10613
First Trust Exchange-Traded Fund II First Trust Indxx Global Natural Resources Income ETF
FTRI
$117M
| $136K | ﹤0.01% |
10,117
-53,501
| -84% | -$707K |
2024 Q1
2 quarters
|
|
|
BZUN
10614
CALL
Baozun
BZUN
$189M
| $136K | ﹤0.01% |
38,100
-32,300
| -46% | -$79.9K |
2016 Q3
32 quarters
|
|
10615
PUT
Corvus Pharmaceuticals
CRVS
$856M
| $136K | ﹤0.01% |
25,800
+10,400
| +68% | +$37.3K |
2023 Q2
5 quarters
|
|
10616
PUT
Select Water Solutions
WTTR
$2.52B
| $136K | ﹤0.01% |
+12,200
| New | +$134K |
2024 Q3
0 quarters
|
|
10617
PUT
Innospec
IOSP
$2.41B
| $136K | ﹤0.01% |
+1,200
| New | +$140K |
2024 Q3
0 quarters
|
|
10618
Vera Therapeutics
VERA
$2.16B
| $136K | ﹤0.01% |
3,070
-1,581
| -34% | -$60K |
2023 Q3
4 quarters
|
|
10619
CVD Equipment Corp
CVV
$29.2M
| $136K | ﹤0.01% |
40,962
+27,313
| +200% | +$101K |
2023 Q4
3 quarters
|
|
|
CASI
10620
DELISTED
CASI Pharmaceuticals
CASI
| $135K | ﹤0.01% |
+22,714
| New | +$147K |
2024 Q3
0 quarters
|
|
10621
Cardiff Oncology
CRDF
$82.5M
| $135K | ﹤0.01% |
50,546
-5,250
| -9% | -$12.4K |
2024 Q2
1 quarter
|
|
10622
PUT
International General Insurance
IGIC
$1.06B
| $135K | ﹤0.01% |
7,100
-7,600
| -52% | -$128K |
2022 Q4
7 quarters
|
|
10623
PUT
Tarsus Pharmaceuticals
TARS
$3.41B
| $135K | ﹤0.01% |
4,100
+2,400
| +141% | +$67.5K |
2022 Q4
7 quarters
|
|
10624
CALL
NewtekOne
NEWT
$317M
| $135K | ﹤0.01% |
10,800
+5,500
| +104% | +$69.8K |
2019 Q4
19 quarters
|
|
10625
CALL
Scansource
SCSC
$1.19B
| $134K | ﹤0.01% |
2,800
+2,100
| +300% | +$99.4K |
2024 Q2
1 quarter
|
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.